What is Variantyx?
Variantyx operates at the intersection of biotechnology and data science, providing advanced whole-genome sequencing diagnostics. Its core value proposition lies in its ability to deliver high-yield, actionable insights for rare genetic disorders, reproductive genetics, and precision oncology. By utilizing a unified whole-genome platform, the company bypasses the limitations of traditional, fragmented testing methodologies. This integrated approach not only enhances diagnostic accuracy but also provides clinicians with a holistic view of a patient's genetic profile, facilitating more personalized and effective treatment pathways. As the healthcare industry shifts toward data-driven, patient-centric models, Variantyx is positioned as a foundational infrastructure provider for modern genomic medicine.
How much funding has Variantyx raised?
Variantyx has raised a total of $130.8M across 7 funding rounds:
Series A
$3M
Series B
$10M
Debt
$350K
Series C
$20M
Other Financing Round
$41.5M
Debt
$20M
Private Equity
$36M
Series A (2017): $3M, investors not publicly disclosed
Series B (2019): $10M led by New Era Capital Partners and Pitango Venture Capital
Debt (2020): $350K supported by PPP
Series C (2021): $20M featuring GHS Fund, Pitango Venture Capital, 20/20 HealthCare Partners, New Era Capital Partners, and IBM Ventures
Other Financing Round (2022): $41.5M backed by Pitango Venture Capital, New Era Capital Partners, Robert Bosch Venture Capital, Peregrine Ventures, and 20/20 HealthCare Partners
Debt (2022): $20M with participation from Kreos Capital Group
Private Equity (2024): $36M led by Peregrine Ventures and New Era Capital Partners
Key Investors in Variantyx
Peregrine Ventures
A specialized life science investment firm that supports companies through various development stages, focusing on bringing groundbreaking healthcare technologies to market.
Pitango Venture Capital
A prominent venture capital firm with dedicated HealthTech funds, providing value-added support to visionary entrepreneurs from stealth mode to maturity.
New Era Capital Partners
A Tel Aviv-based private equity and venture capital firm that provides strategic financial backing to innovative companies within the technology and healthcare sectors.
What's next for Variantyx?
With the recent influx of capital, Variantyx is well-positioned to scale its operational footprint and expand its diagnostic reach. The strategic focus will likely center on enhancing the throughput of its genomic analysis engine and deepening its penetration into the precision oncology market. Furthermore, the company is expected to leverage its strong investor syndicate—which includes seasoned life science venture firms and strategic corporate partners—to navigate regulatory milestones and foster international market adoption. As the company matures, the emphasis will shift toward long-term sustainability and the integration of its diagnostic data into broader clinical decision-support systems, ultimately aiming to set a new standard for genomic-based healthcare delivery.
See full Variantyx company page
